149 related articles for article (PubMed ID: 38828126)
1. Health economic analysis of polygenic risk score use in primary prevention of coronary artery disease - A system dynamics model.
Vernon ST; Brentnall S; Currie DJ; Peng C; Gray MP; Botta G; Mujwara D; Nicholls SJ; Grieve SM; Redfern J; Chow C; Levesque JF; Meikle PJ; Jennings G; Ademi Z; Wilson A; Figtree GA
Am J Prev Cardiol; 2024 Jun; 18():100672. PubMed ID: 38828126
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program.
Mujwara D; Kintzle J; Di Domenico P; Busby GB; Bottà G
Front Public Health; 2023; 11():1139496. PubMed ID: 37497026
[TBL] [Abstract][Full Text] [Related]
3. Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study.
Mujwara D; Henno G; Vernon ST; Peng S; Di Domenico P; Schroeder B; Busby GB; Figtree GA; Bottà G
J Am Heart Assoc; 2022 Jun; 11(12):e025236. PubMed ID: 35699184
[TBL] [Abstract][Full Text] [Related]
4. Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease.
Aragam KG; Dobbyn A; Judy R; Chaffin M; Chaudhary K; Hindy G; Cagan A; Finneran P; Weng LC; Loos RJF; Nadkarni G; Cho JH; Kember RL; Baras A; Reid J; Overton J; Philippakis A; Ellinor PT; Weiss ST; Rader DJ; Lubitz SA; Smoller JW; Karlson EW; Khera AV; Kathiresan S; Do R; Damrauer SM; Natarajan P
J Am Coll Cardiol; 2020 Jun; 75(22):2769-2780. PubMed ID: 32498804
[TBL] [Abstract][Full Text] [Related]
5. Incorporating a polygenic risk score-triaged coronary calcium score into cardiovascular disease examinations to identify subclinical coronary artery disease (ESCALATE): Protocol for a prospective, nonrandomized implementation trial.
Gray MP; Berman Y; Bottà G; Grieve SM; Ho A; Hu J; Hyun K; Ingles J; Jennings G; Kilov G; Levesque JF; Meikle P; Redfern J; Usherwood T; Vernon ST; Nicholls SJ; Figtree GA;
Am Heart J; 2023 Oct; 264():163-173. PubMed ID: 37364748
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
[TBL] [Abstract][Full Text] [Related]
8. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.
Marston NA; Pirruccello JP; Melloni GEM; Koyama S; Kamanu FK; Weng LC; Roselli C; Kamatani Y; Komuro I; Aragam KG; Butterworth AS; Ito K; Lubitz SA; Ellinor PT; Sabatine MS; Ruff CT
JAMA Cardiol; 2023 Feb; 8(2):130-137. PubMed ID: 36576811
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis.
Xia C; Xu Y; Li H; He S; Chen W
Lancet Reg Health West Pac; 2024 Mar; 44():101012. PubMed ID: 38304718
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.
Kiflen M; Le A; Mao S; Lali R; Narula S; Xie F; Paré G
Circ Genom Precis Med; 2022 Oct; 15(5):e003423. PubMed ID: 35904973
[TBL] [Abstract][Full Text] [Related]
11. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
12. Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.
Gao L; Moodie M
Int J Behav Nutr Phys Act; 2022 Dec; 19(1):152. PubMed ID: 36517831
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.
Vassy JL; Posner DC; Ho YL; Gagnon DR; Galloway A; Tanukonda V; Houghton SC; Madduri RK; McMahon BH; Tsao PS; Damrauer SM; O'Donnell CJ; Assimes TL; Casas JP; Gaziano JM; Pencina MJ; Sun YV; Cho K; Wilson PWF
JAMA Cardiol; 2023 Jun; 8(6):564-574. PubMed ID: 37133828
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of system-level mental health strategies for young people in the Australian Capital Territory: a dynamic simulation modelling study.
Crosland P; Ho N; Hosseini SH; Vacher C; Skinner A; Natsky AN; Rosenberg S; Hasudungan R; Huntley S; Song YJC; Lee GY; Marshall DA; Occhipinti JA; Hickie IB
Lancet Psychiatry; 2024 Feb; 11(2):123-133. PubMed ID: 38245017
[TBL] [Abstract][Full Text] [Related]
15. Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease.
Li L; Pang S; Starnecker F; Mueller-Myhsok B; Schunkert H
Eur Heart J; 2024 May; 45(20):1843-1852. PubMed ID: 38551411
[TBL] [Abstract][Full Text] [Related]
16. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
17. Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians.
Wünnemann F; Sin Lo K; Langford-Avelar A; Busseuil D; Dubé MP; Tardif JC; Lettre G
Circ Genom Precis Med; 2019 Jun; 12(6):e002481. PubMed ID: 31184202
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of coronary calcium score-guided statin therapy initiation for Australians with family histories of premature coronary artery disease.
Venkataraman P; Neil AL; Mitchell GK; Stanton T; Nicholls S; Tonkin AM; Watts GF; Marwick TH
Med J Aust; 2023 Mar; 218(5):216-222. PubMed ID: 36841547
[TBL] [Abstract][Full Text] [Related]
19. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
20. Contribution of Lipoprotein(a) to Polygenic Risk Prediction of Coronary Artery Disease: A Prospective UK Biobank Analysis.
Manikpurage HD; Paulin A; Girard A; Eslami A; Mathieu P; Thériault S; Arsenault BJ
Circ Genom Precis Med; 2023 Oct; 16(5):470-477. PubMed ID: 37753708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
